Neurovascular device maker Rapid Medical said it launched a registry study of its Tigertreiver controllable stent retriever.
The Israel-based company touts the Tigertriever as the only controllable, fully-visible stent retriever which can be adjusted by the physician to fit in the dimensions of the blocked blood vessel.
The newly launched European multi-center registry study looks to enroll patients in France and Switzerland, and will be the 1st to examine the use of the Tigertriever in a real-life setting. The company said it has enrolled its 1st patient in the trial at Switzerland’s Cantonal Hospital of Lucerne.
“An 87 year old male was admitted to the hospital with an acute stroke, suffering from severe aphasia and right sided hemiplegia. The patient was treated with the Tigertriever which removed a large clot from his left internal carotid artery in a single attempt. The procedure went very well and took 19 minutes, including placement of a carotid stent due to a severe carotid stenosis. The patient recovered quickly and completely and was even able to sign his consent, to be enrolled in this registry study, 1 hour after finishing the procedure. This is a very exciting and promising device: It is controllable and fully visible. We are happy to have enrolled the 1st patient and to have a leadership role in this registry,” Dr. Alexander von Hessling of the Cantonal Hospital of Lucerne said in a press release.
Rapid Medical said it also plans to initiate a prospective multi-center clinical study as it seeks FDA clearance for the Tigertriver, looking to begin enrollment in the US, Europe and Israel during the 1st half of 2018.
In July, Rapid Medical said it closed a $9 million Series B round of financing to support its minimally invasive stroke treatment and prevention devices.